전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
human cytomegalovirus immunoglobulin i. v.
human cytomegalovirus immunoglobulin i. v.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
human varicella- zoster immunoglobulin i. v.
human varicella-zoster immunoglobulin i. v.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
human tick- borne encephalitis immunoglobulin i. m.
human tick-borne encephalitis immunoglobulin i. m.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
core spc for human normal immunoglobulin for subcutaneous and intramuscular use
note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
título note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use
document title
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
core spc for human plasma derived antithrombin note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use
core spc for human plasma derived antithrombin
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
em genética, ela é uma abreviação de locus, como igl@ para "immunoglobulin lambda locus".
* in genetics, @ is the abbreviation for locus, as in igl@ for "immunoglobulin lambda locus".
마지막 업데이트: 2016-03-03
사용 빈도: 1
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다
as células nk apresentam receptores, denominados killer immunoglobulin-like receptor kir, que são representantes da família das imunoglobulinas presentes na superfície celular.
the nk cells have receptors, denominated 'killer immunoglobulin-like receptors' kir, which belong to the family of the immunoglobulins present on cell surface.
título note for guidance on the clinical investigation of plasma derived antithrombin products core spc for human plasma derived antithrombin note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use core spc for human normal immunoglobulin for subcutaneous and intramuscular use
document title note for guidance on the clinical investigation of plasma derived antithrombin products core spc for human plasma derived antithrombin note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use core spc for human normal immunoglobulin for subcutaneous and intramuscular use
a família dos genes portadores dos domínios mucina e imunoglobulina de células t t-cell immunoglobulin domain and mucin domain - tim consiste de três genes localizados no cromossomo 5q23.
the t-cell immunoglobulin domain and mucin domain tim gene family consists of three genes located on chromosome 5q23.
treatment of short bowel syndrometreatment of mucopolysaccharidosis type ii (hunter syndrome)treatment of multiple myelomatreatment of acute lung injurytreatment of diarrhoea associated with intestinal microsporidial infectiontreatment of acute lymphoblastic leukaemiatreatment of systemic sclerosistreatment of high-grade glioma with subsequent use of ganciclovir sodiumemea/comp validação parecer tempo activo tempo inactivo 12. 07. 2001 30. 07. 2001 26. 10. 2001 89 dias 12. 07. 2001 30. 07. 2001 26. 10. 2001 89 dias 20. 07. 2001 24. 08. 2001 26. 10. 2001 64 dias 09. 08. 2001 24. 08. 2001 26. 10. 2001 64 dias 05. 09. 2001 20. 09. 2001 26. 10. 2001 37 dias 23. 05. 2001 30. 07. 2001 07. 09. 2001 40 dias 27. 03. 2001 24. 08. 2001 21. 11. 2001 90 dias 29. 05. 2001 20. 09. 2001 21. 11. 2001 63 dias 09. 08. 2001 24. 08. 2001 21. 11. 2001 90 dias 28. 08. 2001 20. 09. 2001 21. 11. 2001 62 dias 04. 09. 2001 20. 09. 2001 21. 11. 2001 62 diascomissão europeia parecer recebido data da decisão 05. 11. 200111. 12. 200105. 11. 2001 11. 12. 200105. 11. 2001 11. 12. 200105. 11. 200111. 12. 200105. 11. 2001 11. 12. 200117. 09. 200119. 12. 2001awaiting adoption of european commission decisiondcipromotorindicaçãotreatment of myelodysplastic syndromestreatment of gliomatreatment of pseudomonas aeruginosa lung infection (including colonisation) in cystic fibrosistreatment of familial adenomatous polyposis (fap) .treatment of high-grade dysplasia in barrett's esophagusemea/comp validação parecer tempo activo tempo inactivo 05. 09. 2001 20. 09. 2001 21. 11. 2001 62 dias 12. 10. 2001 26. 10. 2001 18. 12. 2001 54 dias 06. 09. 2001 26. 10. 2001 18. 12. 2001 54 dias 09. 08. 2001 26. 10. 2001 18. 12. 2001 54 dias 11. 10. 2001 26. 10. 2001 18. 12. 2001 54 diascomissão europeia parecer recebido data da decisãoaguarda adopção da decisão da comissão europeia anexo 10 normas orientadoras e documentos de trabalho em 2001grupo de trabalho " biotecnologia " do cpmpnúmero de referência cpmp/bwp/269/95 rev.3 cpmp/bwp/2490/00cpmp/bwp/3088/99emea/410/01 rev.1cpmp/bwp/3207/00título note for guidance on plasma-derived medicinal products note for guidance on cell culture inactivated influenza vaccines annex to note for guidance on harmonisation of requirements for influenza vaccines cpmp/bwp/214/96 note for guidance on the quality, pre-clinical and clinical aspects of gene transfer medicinal products note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products note for guidance on comparability of medicinal products containing biotechnology-derived proteins as drug substancesituação publicado para consulta em janeiro de 2001 publicado para consulta em janeiro de 2001adoptado em abril de 2001adoptado pelo cpmp e o cvmp em maio de 2001adoptado em setembro de 2001grupo de trabalho " produtos derivados do sangue " do cpmpnúmero de referência emea/cpmp/bpwg/283/00emea/cpmp/bpwg/1089/00título note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use note for guidance on the clinical investigation of plasma derived fibrin sealantssituação publicado para consulta em março de 2001publicado para consulta em dezembro de 2001grupo de trabalho " eficácia " do cpmpnúmero de referência emea/cpmp/ewp/552/95 rev.1 emea/cpmp/ewp/49/01emea/cpmp/ewp/18/01cpmp/ewp/567/98 rev.1cpmp/ewp/205/95 rev.1 emea/cpmp/ewp/1045/01emea/cpmp/ewp/967/01emea/cpmp/ewp/512/01emea/cpmp/ewp/788/01emea/cpmp/ewp/2330/99 emea/cpmp/ewp/2284/99emea/cpmp/ewp/phvwp/1417/01emea/cpmp/ewp/1343/01cpmp/ewp/qwp/1401/98 rev.1 emea/cpmp/ewp/561/98emea/cpmp/ewp/1533/01emea/cpmp/ewp/560/98
· iduronate-2-sulfatase· thalidomide·······sponsor· ligand pharmaceuticals· orphan europe sarl· pharm research associates (uk) ltd· tkt uk ltd· kendle international ltd·······indication· treatment of cutaneous t-cell lymphoma· prevention of pseudomonas aeruginosa infections in patients with cystic fibrosis· treatment of short bowel syndrome· treatment of mucopolysaccharidosis type ii (hunter syndrome)· treatment of multiple myeloma· treatment of acute lung injury· treatment of diarrhoea associated with intestinal microsporidial infection· treatment of acute lymphoblastic leukaemia· treatment of systemic sclerosis· treatment of high-grade glioma with subsequent use of ganciclovir sodium· treatment of myelodysplastic syndromes· treatment of gliomaemea/comp · validation · opinion · active time · clock stop · 12.07.2001 · 30.07.2001 · 26.10.2001 · 89 days · 20.07.2001 · 24.08.2001 · 26.10.2001 · 64 days · 09.08.2001 · 24.08.2001 · 26.10.2001 · 64 days · 05.09.2001 · 20.09.2001 · 26.10.2001 · 37 days · 23.05.2001 · 30.07.2001 · 07.09.2001 · 40 days · 27.03.2001 · 24.08.2001 · 21.11.2001 · 90 days · 29.05.2001 · 20.09.2001 · 21.11.2001 · 63 days · 09.08.2001 · 24.08.2001 · 21.11.2001 · 90 days · 28.08.2001 · 20.09.2001 · 21.11.2001 · 62 days · 04.09.2001 · 20.09.2001 · 21.11.2001 · 62 days · 05.09.2001 · 20.09.2001 · 21.11.2001 · 62 days · 12.10.2001 · 26.10.2001 · 18.12.2001 · 54 days